Search Result

Results for "

TT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Aurora Kinase (1) AUTACs (1) Autophagy (1) Cathepsin (1) Drug Derivative (1) FGFR (1) GCGR (2) HSP (1) Integrin (1) Liposome (2) MDM-2/p53 (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) Reactive Oxygen Species (ROS) (1) RET (3) Small Interfering RNA (siRNA) (1) Somatostatin Receptor (2) TNF Receptor (1) Transmembrane Glycoprotein (2) VEGFR (1) YAP (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Cationic Lipids (2) siRNAs (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156483

TT-012 2 Publications Verification	Others	Cancer
TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .

HY-114520

TT01001	Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
TT01001 is a potent and orally active mitoNEET ligand. TT01001 reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 improves type II diabetes without causing weight gain .

HY-125016

TT-10 1 Publications Verification TAZ-K	YAP	Cardiovascular Disease Cancer
TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity. TT-10 can be used for the research of heart diseases accompanied by cardiomyocyte loss .

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Inflammation/Immunology Cancer
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .

HY-148049

TT3	Liposome	Others
TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .

HY-129658A

TT-OAD2	GCGR	Metabolic Disease
TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment .

HY-145601

Tinengotinib TT 00420	Aurora Kinase FGFR VEGFR	Cancer
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC₅₀=1.2-3.3 nM), FGFR1/2/3 (IC₅₀=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .

HY-111203

TT-301 MW189; MW01-6-189WH	Drug Derivative	Others
TT-301 is an active compound.

HY-105172A

TT-232 TFA CAP-232 TFA; TLN-232 TFA	Somatostatin Receptor Apoptosis	Cancer
TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism .

HY-129658

TT-OAD2 free base	GCGR	Metabolic Disease
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment .

HY-P99459

Baminercept 1 Publications Verification BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-RS15240

Ttr Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ttr Rat Pre-designed siRNA Set A contains three designed siRNAs for Ttr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ttr Rat Pre-designed siRNA Set A Ttr Rat Pre-designed siRNA Set A

HY-129652

HaloAUTAC tt15	AUTACs	Cancer
HaloAUTAC tt15 is an autophagy-targeting chimera (AUTAC), that targets the Halo Tag carrying proteins, and degrades via the autophagy mechanism .

HY-101246

RPI-1	RET	Cancer
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .

HY-145798

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide	Liposome	Others
N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 (HY-148049). TT3 is an ionizable lipid-like materials for mRNA delivery .

HY-P5425A

Tetanus Toxin (830–844) TFA	Transmembrane Glycoprotein	Cancer
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 ⁺ T-cell epitope. This promiscuous CD4 ⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 ⁺ T-cell responses in a large part of the human population) .

HY-N2138

Buddlejasaponin IVb	Others	Inflammation/Immunology
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

HY-P4302

Z-FK-ck Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone	Cathepsin	Cardiovascular Disease
Z-FK-ck (Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone) is a potent and selective gingipain-K-specific inhibitor. Z-FK-ck prolongs plasma thrombin time (TT) in a dose- and time-dependent manner .

HY-168728

MAO-B-IN-37	Monoamine Oxidase	Neurological Disease
MAO-B-IN-37 (Compound 37) is a derivative of TT01001 (HY-114520), and a selective inhibitor for monoamine oxidase B (MAO-B) with an IC₅₀ of 270 nM. MAO-B-IN-37 exhibits good metabolic stability in mice microsomes and good affinity with human serum albumin .

HY-156113

RET-IN-25	RET	Cancer
RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC₅₀s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC .

HY-160902

2G-HaloAUTAC	Autophagy	Others
2G-HaloAUTAC (Compound tt44) is a second-generation autophagy-targeting chimera (2G-HaloAUTAC) that improves the activity of AUTACs by replacing the L-Cysteine (L-Cys) linker with other structures. 2G-HaloAUTAC exhibits degradation activity against EGFP-HaloTag protein through an autophagic mechanism .

HY-156135

NSC194598	RET	Others
NSC194598 is a p53 DNA-binding inhibitor with IC₅₀ value of 180 nM and 2-40 μM for in vitro and in vivo, respectively. NSC194598 interferes with transcriptional activation of mutated RET gene in human medullary thyroid carcinoma TT cells. NSC194598 can be used for acute toxicity to normal tissues by radiation and chemotherapy research .

HY-P99160

Labetuzumab	Transmembrane Glycoprotein	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

HY-156906

UNC3474	MDM-2/p53	Cancer
UNC3474 is a small molecule ligand, binding with 53BP1. UNC3474 binds the aromatic methyl-lysine binding cage of 53BP1 ^TT, with a dissociation constant (K_d) of 1.0 ± 0.3 μM. UNC3474 inhibits the recruitment of 53BP1 to DSBs by stabilizing a pre-existing autoinhibited state of 53BP1 in cells .

HY-124611

JG-231	HSP Apoptosis	Cancer
JG-231 is an allosteric inhibitor of heat shock protein 70 (Hsp70). JG - 231 inhibits the binding of Hsp70 and BAG family proteins, including inhibition of Hsp70 and BAG1 with a K_i of 0.11 μM. JG-231 inhibits proliferation of tumor cells and induces apoptosis. JG-231 has antitumor activity .

HY-157172

MorHap	Integrin	Infection Neurological Disease
MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA)-containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection .

Cat. No.	Product Name	Type

HY-148049

TT3	Drug Delivery
TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .

HY-145798

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide	Drug Delivery
N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 (HY-148049). TT3 is an ionizable lipid-like materials for mRNA delivery .

Cat. No.	Product Name	Target	Research Area

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Inflammation/Immunology Cancer
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .

HY-P5425A

Tetanus Toxin (830–844) TFA	Transmembrane Glycoprotein	Cancer
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 ⁺ T-cell epitope. This promiscuous CD4 ⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 ⁺ T-cell responses in a large part of the human population) .

HY-P5425

Tetanus Toxin (830–844)	Peptides	Others
Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)

HY-P4302

Z-FK-ck Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone	Cathepsin	Cardiovascular Disease
Z-FK-ck (Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone) is a potent and selective gingipain-K-specific inhibitor. Z-FK-ck prolongs plasma thrombin time (TT) in a dose- and time-dependent manner .

Cat. No.	Product Name	Target	Research Area

HY-P99459

Baminercept 1 Publications Verification BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-P99160

Labetuzumab	Transmembrane Glycoprotein	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

Buddlejasaponin IVb	Triterpenes Prosopis juliflora (Sw.) DC. Classification of Application Fields Terpenoids Labiatae Dipsacaceae Source classification Plants Dipsacus asper Inflammation/Immunology Disease Research Fields	Others
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

TT3		Cationic Lipids
TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide		Cationic Lipids
N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 (HY-148049). TT3 is an ionizable lipid-like materials for mRNA delivery .

Ttr Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Ttr Rat Pre-designed siRNA Set A contains three designed siRNAs for Ttr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TT

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products